KR102018863B1 - 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 - Google Patents

개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 Download PDF

Info

Publication number
KR102018863B1
KR102018863B1 KR1020157012291A KR20157012291A KR102018863B1 KR 102018863 B1 KR102018863 B1 KR 102018863B1 KR 1020157012291 A KR1020157012291 A KR 1020157012291A KR 20157012291 A KR20157012291 A KR 20157012291A KR 102018863 B1 KR102018863 B1 KR 102018863B1
Authority
KR
South Korea
Prior art keywords
protein
seq
cell
ompt1
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157012291A
Other languages
English (en)
Korean (ko)
Other versions
KR20150064209A (ko
Inventor
크리스토퍼 디. 타노스
크리스토퍼 제이. 머레이
준하오 양
헤더 스티븐슨
Original Assignee
서트로 바이오파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서트로 바이오파마, 인크. filed Critical 서트로 바이오파마, 인크.
Publication of KR20150064209A publication Critical patent/KR20150064209A/ko
Application granted granted Critical
Publication of KR102018863B1 publication Critical patent/KR102018863B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020157012291A 2012-10-12 2013-10-08 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 Active KR102018863B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
US61/713,245 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Publications (2)

Publication Number Publication Date
KR20150064209A KR20150064209A (ko) 2015-06-10
KR102018863B1 true KR102018863B1 (ko) 2019-09-05

Family

ID=49447839

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012291A Active KR102018863B1 (ko) 2012-10-12 2013-10-08 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화

Country Status (14)

Country Link
US (3) US9650621B2 (enExample)
EP (1) EP2906592B1 (enExample)
JP (3) JP6421122B2 (enExample)
KR (1) KR102018863B1 (enExample)
CN (1) CN104837863B (enExample)
AU (1) AU2013329464C1 (enExample)
CA (1) CA2887355C (enExample)
DK (1) DK2906592T3 (enExample)
ES (1) ES2694683T3 (enExample)
HU (1) HUE041721T2 (enExample)
IL (1) IL238095B (enExample)
PL (1) PL2906592T3 (enExample)
SG (1) SG11201502875VA (enExample)
WO (1) WO2014058830A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887355C (en) 2012-10-12 2023-03-07 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression
KR102289258B1 (ko) * 2013-04-19 2021-08-11 서트로 바이오파마, 인크. 상승된 수준의 외인성 샤페론을 갖는 세포 추출물을 이용한 박테리아 세포 비함유 합성 시스템에서의 생물학적 활성 단백질의 발현
EP3164501A4 (en) * 2014-07-02 2018-01-17 Sutro Biopharma, Inc. High growth capacity auxotrophic escherichia coli and methods of use
EP3882343A3 (en) * 2016-01-13 2021-12-08 New England Biolabs, Inc. Thermostable variants of t7 rna polymerase
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
JP7325341B2 (ja) 2017-07-11 2023-08-14 シンソークス，インク． 非天然ヌクレオチドの組み込み及びその方法
BR112020002272A2 (pt) 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
MX2020003810A (es) 2017-10-12 2020-08-13 Vaxcyte Inc Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.
KR102812714B1 (ko) 2018-02-26 2025-05-27 신톡스, 인크. Il-15 접합체 및 이의 용도
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
JP7636323B2 (ja) 2018-11-08 2025-02-26 シンソークス， インコーポレイテッド インターロイキン１０コンジュゲートおよびその使用
CN113660946A (zh) 2019-02-06 2021-11-16 新索思股份有限公司 Il-2缀合物及其使用方法
MX2021012120A (es) 2019-04-02 2021-11-03 Vaxcyte Inc Sintesis optimizada libre de celulas del antigeno b del plasmido de invasion y composiciones y metodos de uso relacionados.
MX2022001776A (es) 2019-08-15 2022-03-17 Synthorx Inc Terapias de combinacion de inmuno oncologia con conjugados de il-2.
JP7758662B2 (ja) 2019-09-10 2025-10-22 シンソークス， インコーポレイテッド Ｉｌ－２コンジュゲートおよび自己免疫疾患を治療するための使用方法
KR20220097445A (ko) 2019-11-04 2022-07-07 신톡스, 인크. 인터류킨 10 접합체 및 이의 용도
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
EP4171648A1 (en) 2020-06-25 2023-05-03 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
AU2021342284A1 (en) * 2020-09-14 2023-04-20 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
MX2023004029A (es) 2020-10-09 2023-04-27 Synthorx Inc Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
EP4225375A1 (en) 2020-10-09 2023-08-16 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
TW202313117A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024196937A1 (en) 2023-03-20 2024-09-26 Synthorx, Inc. Cancer therapy with il-2 peg conjugates
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60040771D1 (de) * 1999-03-04 2008-12-24 Asubio Pharma Co Ltd Verfahren zur kontrolle der spaltung mit ompt protease
WO2002059293A2 (en) 2001-01-25 2002-08-01 Forster Anthony C Process and compositions for peptide, protein and peptidomimetic synthesis
CA2496437C (en) 2002-08-19 2013-01-08 The Board Of Trustees Of The Leland Stanford Junior University Improved methods of in vitro protein synthesis
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
US9657323B2 (en) 2003-09-30 2017-05-23 Daiichi Sankyo Company, Limited Polypeptide cleavage method using OmpT protease variant
DE602006014362D1 (de) * 2005-02-02 2010-07-01 Univ Bayreuth Esterasen zur überwachung der proteinbiosynthese in vitro
AU2006304110B2 (en) * 2005-10-12 2012-02-02 The Scripps Research Institute Selective posttranslational modification of phage-displayed polypeptides
RU2464315C2 (ru) * 2006-03-16 2012-10-20 Зе Скрипс Ресеч Инститьют Генетически запрограммированная экспрессия белков, содержащих не встречающуюся в природе аминокислоту фенилселеноцистеин
EP2376647B1 (en) 2009-01-12 2014-03-05 Sutro Biopharma, Inc. Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
CA2887355C (en) * 2012-10-12 2023-03-07 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Also Published As

Publication number Publication date
AU2013329464C1 (en) 2018-02-15
AU2013329464B2 (en) 2017-07-27
US10450353B2 (en) 2019-10-22
KR20150064209A (ko) 2015-06-10
US11261219B2 (en) 2022-03-01
JP2018029621A (ja) 2018-03-01
HUE041721T2 (hu) 2019-05-28
CN104837863B (zh) 2018-06-19
US20170283469A1 (en) 2017-10-05
AU2013329464A1 (en) 2015-05-14
SG11201502875VA (en) 2015-06-29
EP2906592A1 (en) 2015-08-19
WO2014058830A1 (en) 2014-04-17
CA2887355C (en) 2023-03-07
JP6421122B2 (ja) 2018-11-07
IL238095A0 (en) 2015-05-31
CN104837863A (zh) 2015-08-12
DK2906592T3 (en) 2018-12-10
JP2021003134A (ja) 2021-01-14
CA2887355A1 (en) 2014-04-17
US20200062807A1 (en) 2020-02-27
US9650621B2 (en) 2017-05-16
ES2694683T3 (es) 2018-12-26
IL238095B (en) 2019-11-28
US20150259664A1 (en) 2015-09-17
EP2906592B1 (en) 2018-10-03
JP2015531407A (ja) 2015-11-02
PL2906592T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
KR102018863B1 (ko) 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화
JP7292442B2 (ja) 改変アミノアシルｔＲＮＡ合成酵素およびその用途
KR102289258B1 (ko) 상승된 수준의 외인성 샤페론을 갖는 세포 추출물을 이용한 박테리아 세포 비함유 합성 시스템에서의 생물학적 활성 단백질의 발현
CN102348807B (zh) 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
US20220243244A1 (en) Compositions and methods for in vivo synthesis of unnatural polypeptides
CN107614689A (zh) 用于将非天然氨基酸并入蛋白质中的平台
Cui et al. Semisynthetic tRNA complement mediates in vitro protein synthesis
US20220228148A1 (en) Eukaryotic semi-synthetic organisms
WO2020243026A1 (en) Methods and compositions for manufacturing polynucleotides
US11584921B2 (en) Non-standard amino acid containing compositions and uses thereof
WO2014194129A2 (en) Cell-free synthetic incorporation of non-natural amino acids into proteins
US10731148B2 (en) Use of lambda-gam protein in ribosomal display technology
US20240384267A1 (en) Compositions and methods for multiplex decoding of quadruplet codons
WO2015115661A1 (ja) アゾール誘導体骨格を有するペプチドの製造方法
Exner Incorporation of novel noncanonical amino acids in model proteins using rational and evolved variants of Methanosarcina mazei pyrrolysyl-tRNA synthetase
HK1167003A (en) Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
KR20160025661A (ko) 디제너러시 리프로그래밍을 통한 비천연 단백질 합성 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150511

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181008

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20181008

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181107

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190328

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190530

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190830

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190830

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220718

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230718

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240722

Start annual number: 6

End annual number: 6